• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      VENCLYXTO combinations are the only chemo-free fixed-duration treatments that offer your CLL patients the opportunity for sustained survival without continuous treatment1,4,5

       


      VENCLYXTO (venetoclax) has three licenced indications1

      VENCLYXTO in combination with obinutuzumab (Ven+O) is indicated for the treatment of adult patients with previously untreated CLL

      VENCLYXTO in combination with rituximab (Ven+R) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy

      VENCLYXTO is licensed as monotherapy (Ven mono), for the treatment of adult patients with CLL:

      • in the absence of del(17p) or TP53 mutations and who have failed both chemoimmunotherapy and a BCRI
      • in the presence of del(17p) or TP53 mutations and who are either unsuitable for, or have failed a BCRI

      BRCI=B-cell receptor pathway inhibitor; CLL=Chronic lymphocytic leukaemia; CR=Complete remission; ORR=Overall response rate; PR=Partial response; SmPC=Summary of product characteristics.

      References

      1. VENCLYXTO Summary of Product Characteristics.
      2. Seymour JF et al. N Engl J Med. 2018; 378(12): 1107–20.
      3. Fischer K et al. N Engl J Med. 2019; 380: 2225–36.
      4. Al-Sawaf O et al. EHA2021 Abstract S146. https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/324554/othman.al-sawaf.venetoclax-obinutuzumab.for.previously.untreated.chronic.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dal-sawaf (accessed November 2021).
      5. Kater AP et al. ASH 2020. Oral Abstract 125. Available from: https://ash.confex.com/ash/2020/webprogram/Paper136109.html (accessed November 2021). 

       

       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com

      UK-VNCCLL-220016. Date of preparation: January 2022.